As of 9:30 AM on the 27th, Celltrion Healthcare is trading at 149,500 KRW, down 1.9% from the previous day. The trading volume is 403,304 shares, which is about 17.37% of the previous day's volume. Celltrion Healthcare is known as the exclusive distributor of Celltrion's biosimilars.
On January 25th, Jin Heung-guk, a researcher at Korea Investment & Securities, stated, "Rekkirona can achieve significant sales this year, but due to the nature of the product, it is difficult to maintain this over a long period. However, by moving beyond biosimilars and developing proprietary new drugs, the visibility of long-term growth has increased, leading to a revision of the perpetual growth rate from 3.0% to 3.5%. This indicates that the Celltrion Group's new drug development capabilities are strengthening. The FDA approval application and acquisition for Rekkirona are expected to be key catalysts moving the stock price in the short term." He set the target price for Celltrion Healthcare at 160,000 KRW.
Over the past five days, individual investors have net purchased 65,680 shares of Celltrion Healthcare, while foreigners and institutions have net sold 222,517 shares and net purchased 162,162 shares, respectively.
※ Source: AI Investment Assistant AI Rassiro
※ This article was generated in real-time by an automated article generation algorithm jointly developed by Asia Economy and the financial AI specialist company Thinkpool.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
